检索结果-南通市图书馆

Evaluation.of Ration.l Use of An.iretrovirals before the Dolutegravir Tran.ition.in.kin.hasa, Democratic Republic of Con.o

引用

World Journ.l of AIDS 2021年第2期11卷 41-49页

作者： eri.k n. kamangu Ben.I. Bulan.a Idriss M. Mwan.ut Simplice k. Makoka Gauthier k. Mesia “Focus HIV/AIDS” Research Group Kinshasa Democratic Republic of Congo HIV/AIDS Un.t Service of Molecular Biology Department of Basic Sciences Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of Congo Un.t of Clin.cal Pharmacology an. Pharmacovigilan.e Department of Pharmacology and Therapeutics Faculty of Pharmaceutical Sciences University of Kinshasa Kinshasa Democratic Republic of Congo

Backgroun.: The ultimate goal of An.iRetroViral Treatmen.s (ART) is to achieve complete immun. restoration.an. lastin. viral suppression.in.the in.ected patien.. In.order to en.ure the efficacy, safety an. accessibili... 详细信息

n.>Backgroun.:n.> The ultimate goal of An.iRetroViral Treatmen.s (ART) is to achieve complete immun. restoration.an. lastin. viral suppression.in.the in.ected patien.. In.order to en.ure the efficacy, safety an. accessibility of an.iretroviral drugs (ARVs), it is recommen.ed that they should be prescribed accordin. to n.tion.l guidelin.s;which are evolvin. with the various recommen.ation. of the World Health Organ.zation.(WHO) an. the arrival of n.wer, more effective an. safer molecules. n.>Objective:n.> The objective of this study was to assess the ration.l use of An.iretrovirals in.patien.s treated in.kin.hasa before the use of Dolutegravir within.the n.tion.l program in.order to assess the correct use of these molecules. n.>Methods:n.> This work is a descriptive cross-section.l study to assess the ration.l use of first-lin. ARVs amon. People Livin. with HIV (PLHIV) in.differen. Cen.ers of Treatmen. (ATCs) in.kin.hasa before the in.roduction.of Dolutegravir. The records of patien.s on.ARVs were ran.omly an. ration.lly selected in.12 differen. ATCs for HIV in.kin.hasa accordin. to three cen.ers per district in.the period from Jun. to September 2018. In.ormation.on.use an. con.umption.of ARVs, complian.e with guidelin.s, chan.e of therapeutic combin.tion.as well as their reason. were con.ulted for the presen. study. n.>Results:n.> 507 files of PLHIV were collected in.the various ATCs. 274 (54.1%) were from female patien.s. The most represen.ed age group was 26 to 35 years with 192 patien.s (37.9%). The mean.duration.of first-lin. treatmen. for all patien.s in.luded was 16.30 ± 5.85 mon.hs. The most widely used combin.tion.of ARVs overall was TDF + 3TC + EFV at 45.4%. 305 (60.2%) PLHIV kept the same first-lin. treatmen. molecule throughout the treatmen. period with an.average treatmen. duration.of 12.9 ± 2.77 mon.hs. The most common.combin.tion.foun. in.this population.was TDF + 3TC + EFV (69.2%). 202 (39.8%) PLHIV chan.ed

关键词： Ration.l Use ARVs Dolutegravir kin.hasa

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Profile of Discordan. Couples for Human.Immun.deficien.y Virus In.ection.Followed in.kin.hasa: Case of Mon.ole Medical Cen.er

引用

World Journ.l of AIDS 2023年第3期13卷 125-146页

作者： Isaac T. Woto Cagod B. In.ale Simplice k. Makoka Samclide Mbikayi Berry I. Bon.en.a eri.k n. kamangu Departmen. of Basic Scien.es Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of the Congo Research Group “Focus VIH/SIDA” Kinshasa Democratic Republic of the Congo Faculty of Medicin. Université Technologique Bel Campus Kinshasa Democratic Republic of the Congo Departmen. of In.ectious Diseases Monkole Medical Center Kinshasa Democratic Republic of the Congo Cen.re de Formation.et d’Appui San.taire (CEFA-Mon.ole) Kinshasa Democratic Republic of the Congo

Backgroun.: Programs targetin. serodiscordan. couples in.Africa are n.t a priority in.efforts to preven. Human.Immun.deficien.y Virus (HIV) in.ection. although a large proportion.of these occur in.stable relation.hips, of which serodiscordan.e accoun.s for about two-thirds with a high risk of serocon.ersion.of the seron.gative partn.r. Objective: The objective of this study was to describe the profile of HIV serodiscordan. couples followed in.kin.hasa, DRC. Methods: Descriptive cross-section.l study to describe the profile of differen. heterosexual HIV serodiscordan. couples followed at the Mon.ole Medical Cen.er in.kin.hasa, DRC, from n.vember 2021 to Jun. 2022. The data were collected from the in.ormation.sheets elaborated by the research team as well as from the in.ormation.provided by the computerized files of the patien.s man.ged at the In.ectious Diseases Un.t of the Mon.ole Medical Cen.er after the sign.ture of the in.ormed con.en.. An.average of 8 cc of blood was taken.from a peripheral vein.in.the patien.’s forearm, an. was stored in.EDTA tubes at −20˚C, of which at least 6 mL were used for biochemical an.lyses, 2 spots of 200 μL for each partn.r were stored on.filter paper at −20˚C an. were used for Dn. extraction. n.sted PCR con.irmed the serological diagn.sis. Results: Out of a total of 482 heterosexual couples followed for HIV at the Mon.ole Medical Cen.er, 28 (5.8%) were HIV serodiscordan., of which 14 (2.9%) couples agreed to participate in.the presen. study. The mean.age was 43.39 ± 10 years with extremes ran.in. from 24 to 62 years. The patien.s were main.y from the in.ormal sector (53.6%) an. weighed between.61 an. 71 kg (46.4%). Sexual in.ercourse con.in.ed in.all couples, without con.om use (85.7%) for desire of procreation.(82.1%);although the great majority of HIV-n.gative partn.rs (85.7%) were n.t un.er ARV prophylaxis. Leukopen.a was foun. in.42.9% of HIV-n.gative partn.rs compared to 21% of HIV-positive partn.rs;all partn.rs had a predomin.n

关键词： Discordan. Couple Profile HIV kin.hasa

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Profile of People Livin. with HIV after 24 Weeks of Treatmen. with Dolutegravir in.kin.hasa

引用

Advan.es in.In.ectious Diseases 2023年第4期13卷 660-674页

作者： Berry I. Bon.en.a Ben.it O. kaben.ele Marie-Thérèse A. S. Sombo Guy M. M. Bumoko Hippolyte n. T. Situakiban.a Fridolin.k. k. kodon.i Gauthier k. Mesia Marian. M. Lusakiban.a Jean.Marie n. kayembe Baudouin.B. Buassa Richard L. kalala eri.k n. kamangu Faculty of Medicin. Bel Campus Technological University Kinshasa Democratic Republic of Congo Focus HIV/AIDS Research Group Kinshasa Democratic Republic of Congo Departmen. of In.ern.l Medicin. Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of Congo Departmen. of n.urology Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of Congo Biochemistry Laboratory Faculty of Pharmaceutical Sciences University of Kinshasa Kinshasa Democratic Republic of Congo Clin.cal Pharmacology Un.t Department of Pharmacology Faculty of Medicine and Pharmaceutical Sciences University of Kinshasa Kinshasa Democratic Republic of Congo Service of Molecular Biochemistry Department of Basic Sciences Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of Congo

In.roduction. The sixth mon.h appoin.men. (M6) is crucial because at the start of the ART course, it is an.in.icator of the progn.sis of the evolution.of care an. decision.makin. on.the con.in.ity of treatmen.. Objective: The objective of this study is therefore to presen. the profile of People Livin. with HIV un.er treatmen. with Dolutegravir 6 mon.hs after startin. ART in.kin.hasa. Methods: The presen. study is a cross-section.l view at M6 of a prospective cohort to determin. the profile of People Livin. with HIV (PLHIV) after 6 mon.hs of ARV Treatmen. (ART) in.kin.hasa, DRC. Durin. the M6 appoin.men., from April to August 2022, a sample of 5 ml of blood was taken.for the various an.lyzes from all HIV patien.s in.luded. The collection.of sociodemographic data as well as biological an. clin.cal data was carried out un.er the same con.ition. as at in.lusion. The parameters recorded durin. M6 were: age, sex, an. religion. level of study, marital status, profession. socio-econ.mic level, height, weight, Body Mass In.ex (BMI), clin.cal profile, opportun.stic in.ection. as well as biochemical an. molecular assessmen.. Results: In.M6, 62 patien.s were registered in.ludin. 38 women.(61.3%), thus givin. a sex ratio of 1.58 in.favor of women. Fifty-seven.(57) patien.s did n.t respon. to the appoin.men., represen.in. a loss rate of 47.89%. The most common.age group is between.36 an. 45 years old with 16 patien.s (26.7%). The mean.age was 42.4 ± 13.3 years. The mean.weight was 60.5 ± 15.4 kg with a mean.BMI of 22.6 ± 5.8 kg/m2. Thirty-four (34) patien.s (61.82%) were in.Clin.cal Stage 3. Thirty-six (36) patien.s (67.92%) had a n.rmal clin.cal con.ition. The most common.opportun.stic in.ection. amon. patien.s in.M6 were: skin.pruritus (25.8%), dermatitis (22.6%) an. rash (21%). The mean.values of biochemical parameters of patien.s in.M6 were within.n.rmal ran.es. The median.VL value was 2.92 log10 Rn. copies/ml with 17.75% of patien.s experien.in. major failure of f

关键词： Profile PLHIV 6 Mon.hs of ART Dolutegravir kin.hasa

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Virological an. Molecular Profile of People Livin. with the Human.Immun.deficien.y Virus Startin. Dolutegravir Based An.iretroviral Treatmen. in.kin.hasa, Democratic Republic of Con.o

引用

World Journ.l of AIDS 2023年第3期13卷 83-94页

作者： Berry I. Bon.en.a Charlotte L. Tshin.uta Marie-Thérèse A. S. Sombo Guy M. M. Bumoko Ben.it O. kaben.ele Gauthier k. Mesia eri.k n. kamangu Faculty of Medicin. Bel Campus Technological University Kinshasa Democratic Republic of Congo “Focus HIV/AIDS” Research Group Kinshasa Democratic Republic of Congo Departmen. of n.urology Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of Congo Departmen. of In.ern.l Medicin. University Clinic Faculty of Medicine University of Kinshasa Democratic Republic of Congo Un.t of Pharmacovigilan.e Faculty of Pharmaceutical Sciences University of Kinshasa Kinshasa Democratic Republic of Congo Molecular Biochemistry Service Department of Basic Sciences Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of Congo

Con.ext: Despite the n.w recommen.ation. “Test an. Treat”, the virological an. molecular parameters remain.importan. in.ormation.for An.iretroviral Treatmen. an. adequate for mon.torin. of patien.s in.ected with HIV/AIDS. Objective: the Objective of this study is to presen. the virological an. molecular profile of People Livin. with HIV startin. An.iretroviral Therapy in.kin.hasa in.the era of the Dolutegravir. Methods: This was a tran.versal study to determin. virological an. molecular profile of People Livin. with HIV (PLHIV) startin. an.ARV Treatmen.. The patien.’s in.lusion.period was from October 04, 2021 to February 15, 2022. A sample of 5 ml of blood was taken.in.a tube with EDTA an.icoagulan. for Molecular Biology an.lyzes (Viral Load an. Sequen.in.) in.all HIV patien.s, after readin. an. sign.n. in.ormed con.en.. The population.was made up of adult patien.s over the age of 18, in.ected with HIV an. startin. ART. Results: 119 patien.s (56.3% of women. were in.luded in.this study, thus a sex-ratio of 1.29. The average age of patien.s in.luded was 39.87 ± 12.36 years. The most represen.ed age group is that of 36 to 45 with 37 patien.s (31.9%) followed by that from 26 to 35 years with 24 patien.s (20.7%). Out of 119 patien.s, 21 patien.s had an.un.etectable Viral Load (VL). The median.value of VL was 4.16 log10 Rn. copies/ml. 114 samples were successfully amplified. Subtype A was domin.n. with 23 cases (20.2%);followed by the subtype C an. CRF02_AG each with 14.0%, an. D (10.5 %). k65R (1.8%), T69P/n.(4.4%), k70R (7.9%) an. M184V (7.0%) mutation. were listed as existin. mutation. for n.cleotide Tran.criptase In.ibitors. Con.lusion. 38 patien.s (31.93%) started the TARV with a positive virological progn.sis. The subtype A remain. domin.n. in.kin.hasa with 23 cases (20.2%);followed by the subtype C an. CRF02_AG each with 14.0%. For In.ibitors of Tran.criptase Reverse n.cleotide;k65R, T69P/n. k70E/R an. M184V mutation. were foun. in.patien.s’ n.ive of ARV Treatmen

关键词： Virological Profile Molecular Profile PLHIV Start of ART kin.hasa

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Virological Profile of People Livin. with HIV after 12 Mon.hs of Treatmen. with Dolutegravir in.kin.hasa

引用

World Journ.l of AIDS 2023年第4期13卷 171-177页

作者： Berry I. Bon.en.a Marie-Thérèse A. S. Sombo Guy M. M. Bumoko Ben.it O. kaben.ele eri.k n. kamangu Faculty of Medicin. Bel Campus Technological University Kinshasa Democratic Republic of Congo Focus HIV/AIDS Research Group Kinshasa Democratic Republic of Congo Departmen. of n.urology Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of Congo Service of In.ectious Diseases Department of Internal Medicine University Clinic Faculty of Medicine University of Kinshasa Democratic Republic of Congo Service of Molecular Biochemistry Department of Basic Sciences Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of Congo

Con.ext: The evaluation.of plasma Viral Load con.titutes an.in.icator of the progression.of the in.ection. the effectiven.ss an. the toleran.e of the treatmen.. Objective: The objective of this study is to presen. the virological profile of Patien.s Livin. with HIV (PLHIV) after 12 mon.hs of An.iRetro Viral Treatmen. (ART) based on.Dolutegravir (DTG) in.kin.hasa. Method: The presen. study is a cross-section.l view of the virological profile of the twelfth mon.h of a prospective cohort of PLHIV at M12 of DTG-based ART in.kin.hasa. Durin. the M12 appoin.men., a blood sample was taken.for Molecular Biology an.lyses from all PLHIV in.luded. Result: Durin. the M12 appoin.men., 28 patien.s were registered, in.ludin. 16 (57.1%) women. n.n. (9) patien.s (45.0%) had an.un.etectable Viral Load (VL). The median.VL value was 3.18 log10 Rn. copies/mL (1530 Rn. copies/mL). The mutation. k65R, T69P/n. k70R an. M184V have been.listed as mutation. con.errin. resistan.e to n.cleotide Reverse Tran.criptase In.ibitors. n. mutation. associated with Dolutegravir were observed at M12. Con.lusion. After 12 mon.hs of An.iRetroViral Treatmen. based on.Dolutegravir, half of the Patien.s on.first-lin. ART are in.a state of virological failure.

关键词： Viral Load PLHIV 12 Mon.hs of ART Dolutegravir kin.hasa

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Blood Safety in.the Democratic Republic of the Con.o: Literature Review

引用

Open.Journ.l of Blood Diseases 2023年第3期13卷 102-120页

作者： Alain.k. k. Ilun.a Cagod B. In.ale Tharcise kilara Issac Woto Gisele k. kaben.ele Berry I. Bon.en.a Baudouin.B. T. Buassa Dieudon.é T. n.embue Ben.it O. kaben.ele eri.k n. kamangu In.titute for Research in.Heath Scien.es Kinshasa Democratic Republic of the Congo Service of Molecular Biology Department of Basic Sciences Faculty of Medicine University of Kinshasa Kinshasa Demo-cratic Republic of the Congo “Focus HIV/AIDS” Research Group Kinshasa Democratic Republic of the Congo Faculty of Medicin. Bel Campus Technological University Kinshasa Democratic Republic of the Congo Service of Biochemistry Department of Basic Sciences Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of the Congo Oto-Rhin.-Laryn.ology Service Department of Specialties University Clinics of Kinshasa Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of the Congo Pulmon.logy Service Department of Internal Medicine University Clinics of Kinshasa Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of the Congo

Backgroun.: The Democratic Republic of the Con.o (DRC) faces severe malaria, postpartum haemorrhage, maln.trition.an. sickle cell disease that require tran.fusion. The latter poses immun.logical, in.ectious, metabolic an. hemodyn.mic risks to recipien.s. Objective: To presen. tran.fusion.safety in.the DRC through data from the literature. Methods: This review con.ists of listin. the various articles an. abstracts published on.in. an. presen.ed in.scien.ific con.eren.es havin. as a subject of in.erest tran.fusion.safety in.the DRC. Results: The review is domin.ted by articles from eastern.DRC an. blood mobilization.is aroun. 0.5% of the gen.ral population. All screen.n. tests are serological with a proven.residual risk. The prevalen.e of HIV, HBV, HCV an. syphilis in.ection. is documen.ed at more than.80% an. represen.s respectively 1.9%, 2.96%, 1.89% an. 1.21%. The prevalen.e of other pathogen., the immun.logical an. haemodyn.mic risk are very poorly documen.ed (12.5% to 25%). The prevalen.e of Parvovirus B19 in.ection.is 5.3% an. that of bacterial con.amin.tion.at 1.4%, that of malaria in.estation. between.0.3% an. 28.3%, that of trypan.somiasis at 1.3%, that of babebiosis at 0.17% in.blood don.rs. Allo-immun.zation.represen.s 47.8%, adverse reaction. 3.4%, iron.deficien.y 63.2, iron.deficien.y an.mia 25.9% an. an.mia 36.5%. Pediatrics is the biggest user of this blood. Con.lusion. The prevalen.e of HIV, HBV, HCV an. Syphilis in.ection. is within.the ran.e of sub-Saharan.African.coun.ries. The serological test is systematic an. in.olves the residual risk, it is n.cessary to in.roduce the molecular tests. The prevalen.e of other pathogen. (emergin. viruses, bacteria an. hemoparasites), the immun.logical an. metabolic risk is poorly documen.ed. The search for these pathogen., irregular an.ibodies an. the determin.tion.of ferritin.in.blood don.tion. is n.t systematic.

关键词： Prevalen.e Pathogen. Tran.fusion Democratic Republic of the Con.o

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Profile of People Livin. with Human.Immun.deficien.y Virus In.tiatin. Treatmen. in.the Dolutegravir Era in.kin.hasa, Democratic Republic of Con.o

引用

World Journ.l of AIDS 2023年第3期13卷 95-115页

作者： Berry I. Bon.en.a Ben.it O. kaben.ele Marie-Thérèse A. S. Sombo Guy M. M. Bumoko Hippolyte n. T. Situakiban.a Fridolin.k. k. kodon.i Gauthier k. Mesia Marian. M. Lusakiban.a Jean.Marie n. kayembe Georges L. Mvumbi Baudouin.B. Buassa Richard L. kalala eri.k n. kamangu Faculty of Medicin. Bel Campus Technological University Kinshasa Democratic Republic of Congo “HIV/AIDS Focus” Research Group Kinshasa Democratic Republic of Congo Departmen. of In.ern.l Medicin. Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of Congo Departmen. of n.urology Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of Congo Laboratory of Biochemistry Faculty of Pharmaceutical Sciences University of Kinshasa Kinshasa Democratic Republic of Congo Clin.cal Pharmacology Un.t Department of Pharmacology Faculty of Medicine and Pharmaceutical Sciences University of Kinshasa Kinshasa Democratic Republic of Congo Service of Molecular Biochemistry Department of Basic Sciences Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of Congo

Backgroun.: For several decades, the in.roduction.of An.iRetrovirals (ARVs) has improved the symptomatology of People Livin. with HIV (PLHIV), a spectacular reduction.in.morbidity an. mortality, an.improvemen. in.life expectan.y an. quality of life of PLHIV. Objective: The objective of this study was to determin. the profile of PLHIV in.tiatin. An.iRetroViral Treatmen. (ART) in.the era of Dolutegravir in.kin.hasa. Methods: Cross-section.of a prospective cohort to determin. the profile of PLHIV in.tiatin. ART in.kin.hasa. The in.lusion. were from October 04, 2021 to February 15, 2022. Con.irmation.of the diagn.sis was carried out by n.sted PCR. The in.lusion.criteria were: bein. at least 18 years old, con.irmed HIV positive, n.ïve to ART, con.en.in. an. havin. sign.d an.in.ormed con.en.. The parameters of in.erest followed for the presen. study were: age, sex, religion. level of study, marital status, occupation. height, weight, body mass in.ex (BMI), the clin.cal profile, the opportun.stic in.ection. as well as the para-clin.cal assessmen. (biochemistry an. molecular biology). Results: 67 (56.3%) women.an. 52 (43.7%) men.were in.luded, thus 119 patien.s, all con.irmed positive for HIV by n.sted PCR on.the gag, pol an. en. region.. The average age of the patien.s in.luded is 39.87 ± 12.36 years an. the most represen.ed age group is that of 36 to 45 years with 37 patien.s (31.9%). The average height was 1.66 ± 0.08 meters, with an.average weight of 56.41 ± 13.30 kg, givin. an.average Body Mass In.ex (BMI) of 21.54 ± 5.17 kg/m2. The majority of patien.s were married (46.1%), of Protestan. religion.(70.7%), with secon.ary education.(66.7%), an. workin. in.the in.ormal sector (29.4%). 49 patien.s (41.5%) were in.clin.cal stage 3 an. 55 patien.s (47.0%) had a n.rmal clin.cal status. Malaria (45.4%) an. tuberculosis (29.4%) were the most common.Opportun.stic In.ection.. The mean.values of the patien.s’ assessed biochemical parameters were within.the ran.es. The

关键词： Profile PLHIV Startin. of ART Dolutegravir kin.hasa

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Virological an. Molecular Profile of People Livin. with HIV after 24 Weeks of Treatmen. with Dolutegravir in.kin.hasa

引用

World Journ.l of AIDS 2023年第4期13卷 161-170页

作者： Berry I. Bon.en.a Charlotte Tshin.uta Ben.it O. kaben.ele Marie-Thérèse A. S. Sombo Guy M. M. Bumoko Marian. M. Lusakiban.a Gauthier k. Mesia eri.k n. kamangu Faculty of Medicin. Bel Campus Technological University Kinshasa Democratic Republic of Congo “HIV/AIDS Focus” Research Group Kinshasa Democratic Republic of Congo Departmen. of In.ern.l Medicin. Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of Congo Departmen. of n.urology Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of Congo Clin.cal Pharmacology Un.t Department of Pharmacology Faculty of Medicine and Pharmaceutical Sciences University of Kinshasa Kinshasa Democratic Republic of Congo Service of Molecular Biochemistry Department of Basic Sciences Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of Congo

Con.ext: The appoin.men. of the M6 is crucial because it is an.in.icator of the progn.sis of the evolution.of the care an. the decision.makin. on.the con.in.ation.of the An.iRetroViral Treatmen.. Objective: The objective of this study is therefore to presen. the virological an. molecular profile of People Livin. with HIV un.er treatmen. with Dolutegravir 6 mon.hs after bein. put on.ART in.kin.hasa. Methods: The presen. study is a cross-section.l view at the sixth mon.h of a prospective cohort to determin. the virological an. molecular profile of People Livin. with HIV (PLHIV) after 6 mon.hs of ART based on.Dolutegravir (DTG) in.kin.hasa. A sample of 5 mL of blood was taken.from all HIV patien.s in.luded. The collection.of biological data was carried out un.er the same con.ition. as at in.lusion. After extraction. Quan.itative Real-Time PCR was carried out to determin. the quan.ity of HIV Rn. in.the samples accordin. to the protocols previously described. Reverse Tran.cription.PCR (RT-PCR) an. n.sted PCR were carried out to amplify the region. of in.erest for Protease an. Reverse Tran.criptase for sequen.in.. Results: The median.VL value was 2.92 log10 Rn. copies/mL. With 17.75% of patien.s experien.in. major failure of first-lin. treatmen.. Subtype A is domin.n. with 13 cases (20.98%);followed by CRF_02AG (16.13%), subtypes C (14.52%), D (9.68%) an. k (6.45%). The k65R (3 cases), T69P/n.(6 cases), k70R (9 cases) an. M184V (8 cases) mutation. were listed as existin. mutation. for n.cleotide Reverse Tran.criptase In.ibitors. Con.lusion. After 6 mon.hs of ART, 59.67% of People Livin. with HIV on.Ten.fovir-Lamivudin.-Dolutegravir is in.therapeutic success while 40.33% are in.a state of treatmen. failure. Subtype A remain. domin.n. in.the population.of PLHIV. Resistan.e mutation. were detected for Lamivudin. an. Ten.fovir, but n.n. for Dolutegravir.

关键词： Virological Profile Molecular PLHIV 6 Mon.hs of ART Dolutegravir kin.hasa

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Immun.virologic Evaluation.of Triomun. (Lamivudin., Stavudin. an. n.virapin.) An.iretroviral Therapy in.First Lin. HIV-1 Adult Patien.s in.n.Djamen., Chad

引用

World Journ.l of AIDS 2014年第3期4卷 301-305页

作者： Chatté Adawaye kamangu eri.k Soudy I. Djibrin. Aoudalkarim Moussa Chahad Ali Mahamat Moussa Tchombou HZ Bertin.Vaira Dolores Moutschen.Michel Departmen. of Basic Scien.es Faculty of Medicine University of Kinshasa Kinshasa Democratic Republic of Congo Faculty of Health Scien.es National Reference General Hospital Ndjamena Chad In.titute Un.versity of Scien.es an. Techn.logy of Abeche Abeche Chad Laboratoire AIDS Referen.e CHU Liège Liège Belgium Service In.ectious Diseases an. Gen.ral In.ern.l Medicin. CHU Liège Liège Belgium

Con.exte:?The fight again.t HIV/AIDS epidemics is on. of the greatest challen.es of this cen.ury. The epidemic affects gen.rally un.er-developed coun.ries, an. Sub-Saharan.Africa are the most con.ern.d. The combin.d marketed form kn.wn.as Triomun. was used as first-lin. treatmen. in.several sub-Saharan.African.Coun.ries (60% of VIH in.ected people), in.ludin. Chad. However, n. evaluation.has been.don. for that treatmen. in.the coun.ry. Objective: To evaluate the efficacy an. safety immun.-virological of Triomun. at the Gen.ral Hospital in.n.Djamen./Chad. Methods: 48 HIV-1 positive patien.s eligible for ARV treatmen. were en.olled in.our study, an. they have been.then.followed for 8 mon.hs. We have measured in.these patien.s the CD4 cell coun. before treatmen. an. at the 8th mon.h of treatmen.. After 8 mon.hs of treatmen., we have also evaluated the Lymphocyte T CD4 an. the plasma viral load (VL). Comparison. of mean. of CD4 lymphocytes an. plasma CV (≥1000 copies/ml) were used to defin. treatmen. failure.?Results:?48 patien.s were un.er Triomun. regime. The average CD4 coun. was decreased from 462 ± 179.22 [56 - 981] cells/mm3?before treatmen. to 327.23 ± 153.77 [10 - 1008] cells/mm3?at the 8th mon.h of treatmen.. The mean.plasma viral load for patien.s was 66008.62 copies/ml. The failure rate to Triomun. was 43.75% (21/48).?Con.lusion.?Aside from the side effects already described for Triomun., our study reveals a high treatmen. failure rate. Hen.e, there is the n.ed of regular revision. of therapeutic regime admin.ster in.the first in.en.ion.

关键词： Plasma Viral Load Triomun. An.iretroviral Therapy Virological Failure ARVs HIV-1 First Lin.

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：